Funding for this research was provided by:
Young Scientists Fund (81802863, 82003304)
Natural Science Foundation of Guangdong Province (2018030310285)
Received: 4 September 2021
Accepted: 22 November 2021
First Online: 20 December 2021
: This retrospective cohort study was approved by the institutional review board of Guangzhou Chest Hospital and Nanfang Hospital. Patients had been informed of the possible risks and alternative treatment options before the anti-PD-(L)1 therapy or anti-tuberculosis treatment. All the patients had signed the informed consent for treatments.
: Not applicable.
: The authors declare that they have no competing interests.